Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Real-time Estimate Cboe BZX
Other stock markets
 10:04:43 2024-05-24 am EDT 		5-day change 1st Jan Change
48.44 USD -1.10% Intraday chart for Cytokinetics, Incorporated -18.60% -41.96%
May. 23 Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating MT
May. 23 Sector Update: Health Care Stocks Flat to Lower Premarket Thursday MT

Evolution of the average Target Price on Cytokinetics, Incorporated

Price target over the last 5 years

History of analyst recommendation changes

b.gGDxt_GWuTG0c3wIw2CLKy25VTTO6hjdfvm7WDp_HP4.5xm74qbU0HT2F0x79jnoUmL7FkGH3iq4G5SCAlxOcNPtAqPxmc_uA8FeFw~9b5fff402f27b19d8995dba32cf0c0af

Analyst Recommendations on Cytokinetics, Incorporated

Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating MT
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours MT
Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating MT
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61 MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating MT
SVB Initiates Cytokinetics at Outperform MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.98 USD
Average target price
87.71 USD
Spread / Average Target
+79.06%
High Price Target
122 USD
Spread / Highest target
+149.08%
Low Price Target
60 USD
Spread / Lowest Target
+22.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cytokinetics, Incorporated

Raymond James
Needham & Co.
Oppenheimer
Mizuho Securities
UBS
B. Riley
Truist Securities
HC Wainwright
Cantor Fitzgerald
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
BofA Securities
JMP Securities
Morgan Stanley
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research

Ratings for Cytokinetics, Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. Consensus Cytokinetics, Incorporated